Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides

References

• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352.
   PubMed Web of Science ®Google Scholar
• Mok Y, Ballew SH, Matsushita K. Prognostic value of chronic kidney disease measures in patients with cardiac disease. Circ J. 2017;81(8):1075–1084.
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Bloom R, Muntner P, et al. KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD. Am J Kidney Dis. 2015;65(3):354–366.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease: executive summary. Endocr Pract. 2017;23(4):479–497.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;5:CD007784.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248.
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
   PubMed Web of Science ®Google Scholar
• Epstein M, Vaziri ND. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol. 2012;8(4):214–223.
   PubMed Web of Science ®Google Scholar
• Bulbul MC, Dagel T, Afsar B, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif. 2018;46(2):144–152.
   PubMed Web of Science ®Google Scholar
• Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727–749.
   PubMed Web of Science ®Google Scholar
• Choudhury D, Tuncel M, Levi M. Disorders of lipid metabolism and chronic kidney disease in the elderly. Semin Nephrol. 2009;29(6):610–620.
   PubMed Web of Science ®Google Scholar
• Nguyen SV, Nakamura T, Uematsu M, et al. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. J Cardiol. 2017;69(3):529–535.
   PubMed Web of Science ®Google Scholar
• Russo GT, De Cosmo S, Viazzi F, et al. Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD annals initiative. Diabetes Care. 2016;39(12):2278–2287.
   PubMed Web of Science ®Google Scholar
• Tao-Chun L. Hypertriglyceridemia is a residual risk factor associated with new-onset DKD in type 2 diabetic patients without hypertension [abstract 536-P]. Diabetes. 2017;66(suppl 1):A140.
   Google Scholar
• Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118(1):138–145.
   PubMed Web of Science ®Google Scholar
• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357–366.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
   PubMed Web of Science ®Google Scholar
• Borow KM, Mason RP, Vijayaraghaven K. Eicosapentaenoic acid (EPA) as a potential therapeutic approach to reduce cardiovascular risk in patient with end-stage renal disease on hemodialysis: a review. Cardiorenal Med. 2018;8:18–30.
   Web of Science ®Google Scholar
• Hitoshi S, Chieko N, Hiroaki I, et al. An increase in the EPA/AA ratio is associated with reduction of proteinuria in CKD patients [abstract PS3-202]. Nephrology. 2014;19(suppl 2):166.
   Google Scholar
• Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2017.
   Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37–46.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Braeckman RA, Bays HE, et al. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (The ANCHOR Study). J Clin Lipidol. 2015;9(3):377–383.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Philip S, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016;253:81–87.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10(3):635–645.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
   PubMed Web of Science ®Google Scholar
• Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12(1):100.
   PubMed Web of Science ®Google Scholar
• Braeckman RA, Manku MS, Bays HE, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids. 2013;89(4):195–201.
   PubMed Web of Science ®Google Scholar
• Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(2):101–108.
   PubMed Web of Science ®Google Scholar
• Chung CM, Lin MS, Hsu JT, et al. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol. 2017;11(2):422–431.e2.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association® issues critical updates to the 2019 standards of medical care in diabetes Arlington, VA2019 [ cited 2019 March 27]. Available from: http://www.diabetes.org/newsroom/press-releases/2019/ada-issues-critical-updates-to-2019-standards-of-care.html.
   Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
   PubMed Web of Science ®Google Scholar
• Xu T, Sun Y, Sun W, et al. Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis. Sci Rep. 2016;6:39346.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu Z, Zhang H. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo). 2017;72(1):58–64.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Manku MS, Bays HE, et al. Icosapent ethyl effects on fatty acid profiles in statin-treated patients with high triglycerides: the randomized, placebo-controlled ANCHOR study. Cardiol Ther. 2019;8(1):79–90.
   PubMed Web of Science ®Google Scholar
• Nasu M, Seino K, Tamura Y, et al. Eicosapentaenoic acid restrains the development of the cardiovascular events independent of triglyceride and C-reactive protein reduction in Japanese hemodialysis patients [abstract P1428]. Eur Heart J. 2013;34(suppl 1):271.
   Google Scholar
• Inoue T, Okano K, Tsuruta Y, et al. Eicosapentaenoic acid (EPA) decreases the all-cause mortality in hemodialysis patients. Intern Med. 2015;54(24):3133–3137.
   PubMed Web of Science ®Google Scholar
• Umemoto N, Ishii H, Sakamoto T, et al. Administration of eicosapentaenoic acid reduces cardiovascular and all-cause mortality in chronic hemodialysis patients [abstract P3753]. Eur Heart J. 2015;36(suppl 1):662.
   Google Scholar
• Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
   PubMed Web of Science ®Google Scholar